

DAFTAR PUSTAKA

1. Danastri IGAM, Putra IBD. Inflammatory bowel disease: Foiling inflammatory bowel disease. *Sci Transl Med*. 2013;5(209):1-29.
2. Djojoningrat D. Inflammatory bowel disease : alur diagnosis dan pengobatan di Indonesia. *Buku Ajar Ilmu Penyakit Dalam*. 5th ed. Interna Publishing; 2009:591-7.
3. Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. *Prim Care - Clin Off Pract*. 2017;44(4):673-92.
4. Shapiro JM, Subedi S, LeLeiko NS. Inflammatory bowel diseases. *Gastroenterology*. 2016;37(8):337-46.
5. Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol*. 2015;12(4):205-17.
6. Pratama N, Abdullah M, Kansera DD, Estherina J, Yaruntradhani R, Hardi F, et al. Prevalence of Crohn's disease in Endoscopic Unit Cipto Mangunkusumo Hospital. *Indones J Gastroenterol Hepatol Dig Endosc*. 2011;12(2):85-8.
7. Lelosutan SA. Penyakit Crohn dan kolitis ulseratif. In: *Buku Ajar Gastroenterologi*. 1st ed. Interna Publishing; 2011:427-39.
8. Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. *Expert Review of Gastroenterology & Hepatology*. 2018;12:1079-100
9. Adam SM, Bornemann PH. Ulcerative Colitis. *Mayo Clin Proc*. 2013;87:699-705.
10. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. *J Gastroenterol Hepatol*. 2020;35(3):380-9.
11. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: An overview. *Surg Clin North Am*. 2007;87(3):575-85.
12. Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: The history of inflammatory bowel disease. *J Crohn's Colitis*. 2014;8(5):341-8.
13. Feuerstein JD, Cheifetz AS. Crohn disease: Epidemiology, diagnosis, and management. *Mayo Clin Proc*. 2017;92(7):1088-103.
14. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. *Am Fam Physician*. 2011;84(12):1365-75.
15. Chaubal A, Pandey V, Choksi D, Poddar P, Ingle M, Phadke A, et al. Anemia in patients with ulcerative colitis in remission: A study from western India. *Indian J Gastroenterol*. 2017;36(5):361-5.
16. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. *Am J Gastroenterol*. 2015;110(9):1324-38.

17. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. *Gut*. 2004;53:1-17.
18. Walsh AJ, Bryant R V., Travis SPL. Current best practice for disease activity assessment in IBD. *Nat Rev Gastroenterol Hepatol*. 2016;13(10):567-79.
19. Gisbert JP, Chaparro M. Clinical usefulness of proteomics in inflammatory bowel disease. *J Crohn's Colitis*. 2019;12:374-84
20. Misra R, Faiz O, Munkholm P, Burisch J, Arebi N. Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups. *World J Gastroenterol*. 2018;24(3):424-37.
21. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathology, therapies. *Inflamm Bowel Dis*. 2006;12:3-9.
22. Hein R, Köster I, Bollschweiler E, Schubert I. Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. *Scand J Gastroenterol*. 2014;49(11):1325-35.
23. Abraham C, Cho JH. Mechanism of disease inflammatory bowel disease. *N Engl J Med*. 2009;361(21):2066-78.
24. Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing collateral damage in crohn's disease: The lémann index. *J Crohn's Colitis*. 2016;10(4):495-500.
25. Ungaro R, Mehandru S, Allen PB, Biroulet LP, Colombel JF. Ulcerative colitis. *Lancet*. 2017;389(10080):1756-70
26. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, et al. Clinical characteristics of inflammatory bowel disease in Turkey: A multicenter epidemiologic survey. *J Clin Gastroenterol*. 2009;43(1):51-7.
27. Mitchell PJ, Rabau MY, Haboubi NY. Indeterminate colitis. *Tech Coloproctol*. 2007;11(2):91-6.
28. Mokhtar NM, Nawawi KNM, Verasingam J, Zhiqin W, Sagap I, Azman ZAM, et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. *BMC Public Health*. 2019;19:1-10.
29. Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. *Semin Pediatr Surg*. 2017;26(6):349-55.
30. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. *Scand J Gastroenterol*. 2015;50(8):942-51.
31. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol*. 2011;106:S2-S31.
32. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's disease. *Autoimmun Rev*. 2014;13(4-5):467-71.

33. Moghaddam SN. Inflammatory bowel disease. *Middke East Joiurnal Dig.* 2012;4(2):77-89.
34. Bergeron V, Grondin V, Rajca S, Maubert MA, Pigneur B, Thomas G, et al. Current smoking differentially affects blood mononuclear cells from patients with crohn's disease and ulcerative colitis: Relevance to its adverse role in the disease. *Inflamm Bowel Dis.* 2012;18(6):1101-11.
35. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: A prospective cohort study. *Gut.* 1999;45(2):218-222.
36. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. *Clin Gastroenterol Hepatol.* 2004;2(1):41-8.
37. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. *Gastroenterology.* 2019;157(3):647-59
38. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: A meta-analysis. *Am J Gastroenterol.* 2008;103(9):2394-400.
39. Loftus E V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology.* 2004;126(6):1504-17.
40. Baumgart DC, Sandborn WJ. Crohn's disease. *Lancet.* 2012;380(9853):1590-605.
41. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. *Disease-a-Month.* 2018;64(2):20-57.
42. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fucss CS, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease ulcerative colitis: A cohort study. *Ann Intern Med.* 2012;23(1):1-7.
43. Li N, Shi RH. Updated review on immune factors in pathogenesis of Crohn,s disease. *World J Gastroenterol.* 2018;24(1):15-22.
44. Hsu CH, Jeng YM, Ni YH. Clostridium difficile infection in a patient with Crohn disease. *J Formos Med Assoc.* 2012;111(6):347-9.
45. Veauthier B, Hornecker JR. Crohn's disease : Diagnosis and management. *Am Fam Physician.* 2018;98(11):661-9.
46. Lichtenstein GR, Loftus E V., Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn's disease in adults. *Am J Gastroenterol.* 2018;113(4):481-517.
47. Sands BE. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. *Gastroenterology.* 2004;126(6):1518-32.
48. Danese S, Fiorino G, Mary JY, Lakatos PL, Haens GD, Moja L, et al. Development of red flags index for early referral of adults with symptoms

- and signs suggestive of Crohn's disease: An IOIBD initiative. *J Crohn's Colitis*. 2015;9(8):601-606.
49. Stange EF, Travis SPL, Vermeire S, Beglinger C, Kupcinkas L, Geboesk K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. *Gut*. 2006;55(SUPPL. 1):1-15.
 50. Kallel L, Ayadi I, Matri S, Monia F, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: A prospective study. *Eur J Gastroenterol Hepatol*. 2010;22(3):340-5.
 51. Panés J, Bouzas R, Chaparro M, Sanchez VG, Gisbert JP, Guerenu BMD, et al. Systematic review: The use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. *Aliment Pharmacol Ther*. 2011;34(2):125-45.
 52. Sandborn WJ. Crohn's disease evaluation and treatment: Clinical decision tool. *Gastroenterology*. 2014;147(3):702-5.
 53. Cheifetz AS. Management of active Crohn disease. *JAMA*. 2013;309(20):2150-8.
 54. Shah ED, Siegel CA, Chong K, Melmed GY. Patients with Crohn's disease are more likely to remain on biologics than immunomodulators: A Meta-analysis of treatment durability. *Dig Dis Sci*. 2015;60(8):2408-18.
 55. Gionchetti P, Dignass A, Danese S, Dias FJM, Rogler G, Lakatos PL, et al. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations. *J Crohn's Colitis Adv Access*. <http://ecco-jcc-oxfordjournal.org/>. Diakses Februari 2021
 56. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *Lancet*. 2012;380(9853):1606-19.
 57. Eisenstein M. Ulcerative colitis: towards remission. *Nature*. 2018;563(7730):S33.
 58. Collins P, Rhodes J. Ulcerative colitis: diagnosis and management *BMJ*. 2006;333:340-3.
 59. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with *Clostridium difficile* in patients with inflammatory bowel disease. *Gut*. 2008;57(2):205-10.
 60. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of *Clostridium difficile* infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol*. 2008;103(6):1443-50.
 61. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboesk K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. *J Crohn's*

- Colitis*. 2012;6(10):965-90.
62. Yamamoto-Furusho J., Gutiérrez-Grobe Y, López-Gómez J., Bosques-Padilla F, Rocha-Ramírez. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. *Rev Gastroenterologia Mex*. 2018;83(2):144-67.
 63. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. *J Crohn's Colitis*. 2013;7(7):556-85.
 64. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2016;14(9):1245-55.
 65. Øresland T, Bemelman W, Sampietro G, Spinelli A, Windsor A, Turet E, et al. European evidence based consensus on surgery for ulcerative colitis. *J Crohn's Colitis*. 2015;9(1):4-25.
 66. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. *Ann N Y Acad Sci*. 2019;1450(1):15-31.
 67. Domenica Cappellini M, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging? *Semin Hematol*. 2015;52(4):261-9.
 68. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. *Nat Rev Gastroenterol Hepatol*. 2010;7(11):599-610.
 69. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. *Am J Gastroenterol*. 2008;103(5):1299-307.
 70. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV et al. ASGE guideline: Endoscopy in the diagnosis and treatment of inflammatory bowel disease. *Gastrointest Endosc*. 2006;63(4):558-65.
 71. Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. *World J Gastroenterol*. 2018;24(35):4014-120.
 72. Rejchrt S, Bureš J, Široký M, Kopáčová M, Slezák L, Langr F. A prospective, observational study of colonic mucosal abnormalities associated with orally administered sodium phosphate for colon cleansing before colonoscopy. *Gastrointest Endosc*. 2004;59(6):651-4.
 73. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut*. 2011;60(5):571-607.
 74. Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in inflammatory bowel disease. *Gastrointest Endosc*. 2015;81(5):1101-21.

75. Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: Report of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. *J Pediatr Gastroenterol Nutr.* 2007;44(5):653-74.
76. Haskell H, Andrews CW, Ready SI, Dendrinis K, Farraye FA, Stucchi AF, et al. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. *Am J Surg Pathol.* 2005;29(11):1472-81.
77. Dahlan M. Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan. 4th ed. Epidemiologi Indonesia; 2016.
78. Zeng Z, Zhu Z, Yang Y, Peng X, Su Y, Peng L et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study. *J Gastroenterol Hepatol.* 2013;28(7):1148-53.
79. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. *J Gastroenterol.* 2009;44(7):659-65.
80. Kim HJ, Hann HJ, Hong SN, Kim KH, Ahn IM, Song JY, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: A nationwide population-based study. *Inflamm Bowel Dis.* 2015;21(3):623-30.
81. Sonnenberg A. Age distribution of IBD hospitalization. *Inflamm Bowel Dis.* 2010;16(3):452-7.
82. Ho PYM, Hu W, Lee YY, Gao C, Tan YZ, Cheen HH, et al. Health-related quality of life of patients with IBD in Singapore. 2019;17(1):107-18.
83. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. *Am J Gastroenterol.* 2012;107(9):1399-406.
84. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. *Arch Dis Child.* 2003;88:995-1000.
85. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. *Nat Rev Gastroenterol Hepatol.* 2013;10(10):585-95.
86. Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- α treatment. *Haematologica.* 2010;95(2):199-205.
87. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: A systematic review and individual patient data meta-analysis. *Inflamm Bowel Dis.* 2014;20(5):936-45.

88. Damião AOMC, De Azevedo MFC, De Sousa Carlos A, Wada MY, Silva TVM, De Castro Feitosa F. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. *World J Gastroenterol*. 2019;25(9):1142-57.
89. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: A Review. *J Crohn's Colitis*. 2015;9(6):507-15.

